studi
present
dog
vaccin
leishmania
leishmania
chagasi
challeng
infect
use
prepar
leishmania
braziliensi
promastigot
protein
saponin
adjuv
lbsap
vaccin
lbsap
induc
promin
type
immun
respons
character
increas
level
interleukin
il
interferon
gamma
product
peripher
blood
mononuclear
cell
pbmc
upon
stimul
solubl
vaccin
antigen
importantli
result
show
type
respons
sustain
challeng
infect
day
l
chagasi
challeng
infect
pbmc
lbsap
vaccin
dog
produc
concomit
nitric
oxid
stimul
leishmania
antigen
compar
pbmc
respect
control
group
saponin
lbtreat
nontreat
control
dog
moreov
transform
growth
factor
tgf
decreas
supernat
slcastimul
pbmc
lbsap
group
day
bone
marrow
parasitolog
analysi
reveal
decreas
frequenc
parasit
presenc
vaccin
antigen
conclud
vaccin
dog
lbsap
vaccin
induc
longlast
type
immun
respons
l
chagasi
challeng
infect
crown
studi
present
dog
vaccin
leishmania
leishmania
chagasi
challeng
infect
use
prepar
leishmania
braziliensi
promastigot
protein
saponin
adjuv
lbsap
vaccin
lbsap
induc
promin
type
immun
respons
character
increas
level
interleukin
il
interferon
gamma
product
peripher
blood
mononuclear
cell
pbmc
upon
stimul
solubl
vaccin
antigen
importantli
result
show
type
respons
sustain
challeng
infect
day
l
chagasi
challeng
infect
pbmc
lbsap
vaccin
dog
produc
concomit
nitric
oxid
stimul
leishmania
antigen
compar
pbmc
respect
control
group
saponin
lbtreat
nontreat
control
dog
moreov
transform
growth
factor
tgf
decreas
supernat
slcastimul
pbmc
lbsap
group
day
bone
marrow
parasitolog
analysi
reveal
decreas
frequenc
parasit
presenc
vaccin
antigen
conclud
vaccin
dog
lbsap
vaccin
induc
longlast
type
immun
respons
l
chagasi
challeng
infect
crown
copyright
publish
elsevi
bv
right
reserv
viscer
leishmaniasi
zoonot
featur
caus
protozoan
speci
belong
complex
leishmania
donovani
leishmania
infantum
syn
leishmania
chagasi
latin
america
wide
distribut
mediterranean
basin
middl
east
south
america
desjeux
canin
main
reservoir
parasit
differ
geograph
region
globe
play
relev
role
transmiss
human
dean
dantastorr
thu
current
strategi
control
diseas
includ
detect
elimin
seroposit
dog
alongsid
vector
control
therapi
human
infect
tesh
chemotherapi
dog
still
provid
parasitolog
cure
noli
auxilia
reason
vaccin
viscer
leishmaniasi
vl
would
import
tool
control
canin
viscer
leishmaniasi
cvl
would
also
dramat
decreas
infect
pressur
l
chagasi
human
hommel
et
al
dye
toward
purpos
establish
biomark
immunogen
consid
critic
analyz
candid
vaccin
cvl
rei
et
al
maia
campino
strategi
use
identifi
pattern
immun
respons
dog
search
vaccin
candid
cvl
rei
et
al
sever
studi
report
potenti
differ
cvl
vaccin
trigger
immunoprotect
mechan
leishmania
infect
borjacabrera
et
al
rafati
et
al
holzmul
et
al
giunchetti
et
al
lemesr
et
al
et
al
et
al
fernand
et
al
giunchetti
et
al
b
polar
immun
respons
describ
mous
model
leishmania
infect
mosman
et
al
barral
et
al
kane
mosser
murray
et
al
trinchieri
occur
dog
differ
studi
demonstr
simultan
presenc
interferon
ifn
interleukin
il
chamizo
et
al
lage
et
al
menezessouza
et
al
addit
mix
profil
cytokin
describ
cvl
high
level
transform
growth
factor
tgf
concomit
reduc
express
accord
skin
parasit
load
menezessouza
et
al
studi
evalu
biomark
immunogen
induc
lbsap
vaccin
compos
l
braziliensi
promastigot
protein
plu
saponin
adjuv
demonstr
higher
level
circul
lymphocyt
b
lymphocyt
increas
level
leishmaniaspecif
cell
giunchetti
et
al
lbsap
vaccin
consid
safe
administr
without
induct
ulcer
lesion
site
inocul
vitorianosouza
et
al
moreov
lbsap
vaccin
dog
present
high
low
express
spleen
signific
reduct
parasit
load
organ
roatt
et
al
addit
lbsap
display
strong
sustain
induct
humor
immun
respons
increas
level
antileishmania
total
igg
well
experiment
challeng
roatt
et
al
consid
promis
result
lbsap
vaccin
aim
evalu
immunogen
biomark
experiment
l
chagasi
challeng
thu
profil
differ
cytokin
tumor
necrosi
factor
tnf
nitric
oxid
supernat
peripher
blood
mononuclear
cell
pbmc
cultur
evalu
first
immun
day
complet
vaccin
protocol
time
point
day
experiment
l
chagasi
challeng
frequenc
parasit
bone
marrow
also
evalu
anim
vaccin
experiment
challeng
l
chagasi
plu
saliva
lutzomyia
longipalpi
twenti
male
femal
mongrel
dog
born
rear
kennel
instituto
de
exata
e
universidad
feder
de
ouro
preto
ouro
preto
mina
gerai
brazil
treat
month
anthelmint
vaccin
rabi
tecpar
curitibapr
brazil
canin
distemp
type
adenoviru
coronaviru
parainfluenza
parvoviru
leptospira
vanguard
htlp
pfizer
anim
health
new
york
ny
usa
absenc
specif
antileishmania
antibodi
confirm
indirect
fluoresc
immunoassay
experiment
dog
divid
four
experiment
group
control
c
group
n
receiv
ml
steril
salin
ii
lb
group
n
receiv
g
l
braziliensi
promastigot
protein
ml
steril
salin
iii
sap
group
n
receiv
mg
saponin
sigma
chemic
co
st
loui
mo
usa
ml
steril
salin
iv
lbsap
group
n
receiv
g
l
braziliensi
promastigot
protein
mg
saponin
ml
steril
salin
anim
receiv
subcutan
inject
right
flank
interv
week
total
three
inject
challeng
experiment
anim
perform
day
vaccin
protocol
sens
dog
receiv
intraderm
promastigot
l
chagasi
stationari
phase
cultiv
inner
side
left
ear
addit
acini
salivari
gland
l
longipalpi
preliminari
stage
studi
perform
promastigot
l
braziliensi
maintain
vitro
cultur
nnnlit
media
previous
describ
briefli
parasit
harvest
centrifug
g
min
c
cultur
wash
three
time
salin
buffer
fulli
disrupt
ultrasound
treatment
w
min
c
separ
aliquot
store
c
requir
use
protein
concentr
determin
accord
method
lowri
lowri
et
al
lbsap
vaccin
previous
describ
giunchetti
et
al
regist
instituto
nacion
da
propriedad
industri
brazil
patent
number
pi
februari
peripher
blood
sampl
collect
first
immun
day
complet
vaccin
protocol
time
point
day
experiment
l
chagasi
challeng
punctur
jugular
vein
steril
heparin
ml
syring
obtain
pbmc
vitro
analysi
blood
collect
ad
ml
ficollhypaqu
histopaqu
sigma
subject
centrifug
g
min
room
temperatur
separ
pbmc
resuspend
gibco
medium
wash
twice
rpmi
centrifug
g
min
room
temperatur
homogen
final
resuspend
rpmi
cellsml
previous
describ
vitro
assay
perform
flatbottom
tissu
cultur
plate
costar
cambridg
usa
well
contain
l
cultur
medium
fetal
bovin
streptavidinpenicillin
mm
lglutamin
rpmi
l
pbmc
cellswel
l
vaccin
solubl
antigen
vsa
l
braziliensi
gml
l
solubl
l
chagasi
antigen
slca
gml
obtain
accord
rei
et
al
rei
et
al
b
onehundr
l
rpmi
ad
place
antigen
stimulu
nonstimul
control
cultur
incub
carri
humidifi
incub
co
c
day
supernat
collect
store
freezer
c
detect
cytokin
vitro
evalu
perform
supernat
pbmc
collect
store
describ
cytokin
level
determin
enzymelink
immunosorb
assay
elisa
purchas
r
system
minneapoli
mn
usa
accord
manufactur
instruct
duoset
elisa
use
analysi
anticanin
immunoassay
catalog
number
anticanin
catalog
number
anticanin
catalog
number
anticanin
catalog
number
cytokin
level
quantifi
elisa
use
quantikin
kit
mouseratporcinecanin
immunoassay
catalog
number
cytokin
evalu
use
monoclon
anticanin
antibodi
catalog
number
captur
antibodi
recombin
canin
catalog
number
obtain
standard
curv
biotinyl
anticanin
antibodi
catalog
number
streptavidin
r
system
substrat
solut
mixtur
h
tetramethylbenzidin
product
code
lot
minimum
sensit
pgml
pgml
pgml
pgml
pgml
pgml
experi
perform
use
plate
costar
washington
dc
accord
r
system
instruct
read
perform
use
micropl
automat
reader
biotek
winosski
vt
wavelength
nm
quantif
level
perform
indirectli
measur
nitrit
supernat
pbmc
cultur
griess
reaction
green
et
al
gutman
hollywood
duplic
sampl
grown
bottom
well
nunc
napervil
il
briefli
aliquot
cellfre
cultur
supernat
mix
l
griess
reagent
sulfanylamid
naphthylethylenediamidedihydrochlorid
phosphor
acid
sigma
follow
min
incub
room
temperatur
dark
absorb
measur
nm
use
micropl
reader
biotek
concentr
nitrit
determin
interpol
standard
curv
construct
use
sodium
nitrit
solut
known
concentr
rang
discount
interfer
nitrit
alreadi
present
cultur
medium
data
calcul
take
account
blank
experi
assay
use
medium
employ
vitro
pbmc
cultur
result
first
express
nitrit
concentr
bone
marrow
obtain
evalu
frequenc
tissu
parasit
differ
group
dog
anesthet
intraven
dose
mgkg
bodi
weight
sodium
thiopent
thionembut
abbott
laboratori
paulo
brazil
bone
marrow
fluid
remov
iliac
crest
asept
condit
bone
marrow
aspir
use
studi
presenc
l
chagasi
parasit
pcr
dna
bone
marrow
sampl
extract
wizard
tm
genom
dna
purif
kit
promega
madison
wi
usa
accord
manufactur
instruct
pcr
perform
previous
describ
degrav
et
al
use
primer
forward
ggg
gt
aggggcgttct
gc
revers
amplifi
dna
fragment
base
pair
bp
conserv
region
leishmania
minicircl
kdna
briefli
pcr
assay
reaction
mixtur
contain
l
dna
prepar
mm
dntp
mm
trishcl
ph
mm
kcl
mm
mgcl
pmol
primer
u
taq
polymeras
invitrogen
final
volum
l
pcr
amplif
perform
veriti
thermal
cycler
thermocycl
appli
biosystem
irvin
ca
usa
cycl
consist
min
c
denatur
min
c
anneal
min
c
extens
min
c
final
extens
posit
genom
dna
l
chagasi
neg
without
dna
control
includ
test
amplifi
fragment
analyz
electrophoresi
tabl
level
pbmc
dog
first
vaccin
dose
follow
complet
vaccin
protocol
earli
late
time
point
follow
l
chagasi
challeng
result
present
regard
stimul
solubl
l
chagasi
antigen
slca
follow
group
c
control
lbsap
kill
l
braziliensi
vaccin
plu
saponin
polyacrylamid
gel
ethidium
bromidestain
pcr
product
identif
parasitolog
investig
perform
day
l
chagasi
challeng
statist
analys
perform
use
prism
softwar
packag
prism
softwar
irvin
ca
usa
normal
data
demonstr
use
kolmogorovsmirnoff
test
pair
ttest
use
evalu
differ
mean
valu
cytokin
level
consid
compar
analysi
fig
fig
fig
group
evalu
unpair
ttest
use
evalu
differ
mean
valu
tabl
analysi
varianc
anova
test
follow
tukey
multipl
comparison
use
evalu
differ
treatment
group
cytokin
fig
nitric
oxid
fig
analysi
differ
consid
signific
p
valu
determin
impact
lbsap
vaccin
immun
respons
evalu
cytokin
profil
supernat
pbmc
stimul
vsa
fig
slca
fig
context
perform
compar
analysi
addit
comparison
experiment
group
time
point
comparison
sap
group
show
increas
level
p
product
vsa
stimul
addit
lb
group
present
higher
level
p
vsastimul
pbmc
compar
contrast
slcastimul
cultur
lb
group
display
lower
level
compar
slcastimul
cultur
p
interestingli
lbsap
vaccin
induc
higher
level
vsastimul
pbmc
similarli
presenc
slca
increas
level
p
observ
lbsap
group
comparison
experiment
group
differ
time
point
reveal
increas
level
p
vsastimul
cultur
lb
group
compar
c
group
interestingli
higher
p
level
cytokin
observ
vsastimul
cultur
lbsap
group
compar
c
sap
group
similarli
slcastimul
cultur
lbsap
group
display
increas
p
level
relat
c
sap
lb
group
addit
lbsap
group
show
increas
p
level
relat
c
sap
group
addit
reduc
p
level
compar
lb
group
vsastimul
cultur
earli
immun
respons
l
chagasi
challeng
analyz
differ
group
determin
cytokin
pattern
supernat
pbmc
compar
differ
treatment
vsa
fig
slca
fig
differ
time
point
differ
experiment
group
time
point
comparison
show
c
group
increas
level
product
p
lower
level
product
p
upon
vsa
slca
stimul
addit
c
group
higher
level
slcastimul
pbmc
p
higher
level
product
vsastimul
pbmc
p
sap
group
show
increas
level
p
product
reduct
level
slcastimul
cultur
sap
group
present
higher
level
p
lb
group
show
increas
level
p
product
reduct
vsastimul
pbmc
cultur
stimul
slca
lb
group
shown
increas
level
p
interestingli
lbsap
vaccin
induc
higher
level
pbmc
stimul
vsa
furthermor
presenc
slca
lbsap
vaccin
induc
higher
level
p
reduc
level
occur
group
retain
p
lbsap
group
stimuli
vsa
slca
compar
analysi
experiment
group
show
increas
level
p
slcastimul
cultur
lb
group
vsastimul
cultur
lbsap
group
relat
c
group
interestingli
slcastimul
pbmc
lbsap
group
show
increas
level
p
compar
lb
sap
group
furthermor
increas
level
p
lbsap
compar
c
sap
lb
group
observ
lbsap
vaccin
elicit
longlast
type
immun
respons
display
higher
level
ifn
late
immun
respons
l
chagasi
challeng
studi
differ
group
regard
cytokin
xaxi
display
cytokin
evalu
yaxi
repres
mean
valu
pgml
sd
group
five
animalsevalu
time
left
yax
depict
level
right
yax
repres
cytokin
level
signific
differ
p
valu
measur
first
dose
day
third
dose
indic
connect
line
wherea
symbol
c
sap
lb
indic
signific
differ
relat
c
sap
lb
group
respect
stimulu
time
evalu
level
supernat
pbmc
treat
vsa
fig
slca
fig
data
compar
besid
comparison
experiment
group
time
comparison
result
show
c
group
increas
level
vsastimul
pbmc
p
decreas
level
product
p
presenc
slca
sap
lb
group
present
increas
level
p
presenc
vsa
stimulu
compar
presenc
slca
stimulu
lb
group
decreas
level
p
xaxi
depict
cytokin
evalu
yaxi
repres
mean
valu
pgml
sd
group
five
animalsevalu
time
left
yax
illustr
level
right
yax
repres
cytokin
level
signific
differ
p
valu
measur
first
dose
day
l
chagasi
challeng
indic
connect
line
wherea
symbol
c
sap
lb
indic
signific
differ
relat
c
sap
lb
group
respect
stimulu
time
evalu
compar
similarli
group
lbsap
decreas
level
p
compar
differ
observ
presenc
vsa
stimulu
interestingli
group
level
presenc
vsa
presenc
slca
higher
compar
p
wherea
timedelay
respons
postchalleng
l
chagasi
result
indic
immun
respons
predominantli
type
induc
vaccin
lbsap
compar
analysi
experiment
group
show
increas
p
level
vsastimul
cultur
lb
group
relat
c
group
interestingli
increas
p
level
xaxi
display
cytokin
evalu
yaxi
repres
mean
valu
pgml
sd
group
five
animalsevalu
time
left
yax
illustr
level
right
yax
repres
cytokin
level
signific
differ
p
valu
measur
first
dose
day
l
chagasi
challeng
indic
connect
line
wherea
symbol
c
sap
lb
indic
signific
differ
relat
c
sap
lb
group
respect
stimulu
time
evalu
lbsap
group
observ
relat
c
sap
lb
group
slcastimul
pbmc
level
shown
tabl
focus
analysi
use
supernat
pbmc
simul
slca
evalu
data
use
compar
analysi
control
lbsap
group
well
l
chagasi
challeng
interestingli
decreas
group
immun
lbsap
compar
group
c
sinc
product
consid
key
element
mechan
mediat
elimin
intracellular
pathogen
level
antimicrobi
oxid
produc
vitro
antigenstimul
pbmc
deriv
dog
vaccin
lbsap
determin
fig
reduct
p
observ
level
reactiv
vsastimul
cultur
compar
respect
control
cultur
group
c
sap
lb
lbsap
fig
significantli
increas
nitrit
level
p
vsaand
slcastimul
cultur
observ
sap
group
compar
cultur
receiv
stimuli
c
lb
group
slcastimul
cultur
c
lb
group
show
signific
reduct
level
compar
respect
control
cultur
fig
addit
c
group
present
higher
level
control
cultur
relat
vsastimul
cultur
fig
interestingli
lbsap
group
higher
p
level
level
record
supernat
slcaand
vsastimul
cultur
compar
cultur
receiv
stimuli
group
c
lb
parasitolog
investig
perform
day
l
chagasi
challeng
two
dog
group
c
four
dog
group
sap
one
dog
lb
lbsap
group
diagnos
posit
interest
note
also
period
accompani
experiment
group
remain
asymptomat
increas
vl
incid
world
especi
brazil
motiv
studi
evalu
anticvl
vaccin
epidemiolog
import
dog
biolog
cycl
parasit
palatnikdesousa
aim
guid
rational
develop
anticvl
vaccin
studi
perform
identifi
biomark
immunogen
l
chagasi
challeng
gutman
hollywood
rei
et
al
type
type
immun
respons
immunomodulatori
cytokin
consid
main
target
identifi
resist
biomark
follow
vaccin
cvl
rei
et
al
fernand
et
al
carrillo
et
al
de
lima
et
al
result
previou
studi
use
lbsap
anticvl
vaccin
show
high
immunogen
potenti
induct
increas
level
circul
lymphocyt
b
lymphocyt
higher
level
cell
leishmania
specif
roatt
et
al
studi
lbsap
vaccin
elicit
strong
antigen
relat
increas
level
antileishmania
igg
isotyp
vaccin
strong
sustain
induct
humor
immun
respons
experiment
challeng
increas
level
antileishmania
total
igg
roatt
et
al
furthermor
lbsap
vaccin
dog
present
high
low
express
spleen
signific
reduct
parasit
load
organ
roatt
et
al
addit
lbsap
vaccin
display
safeti
secur
administr
vitorianosouza
et
al
moreira
et
al
howev
studi
evalu
cytokin
profil
associ
cvl
anticvl
vaccin
might
serv
biomark
identifi
resist
suscept
thu
studi
aim
evalu
cytokin
profil
induc
immun
experiment
challeng
l
chagasi
sand
fli
saliva
addit
frequenc
bone
marrow
parasit
includ
evalu
thu
perform
compar
analysi
cytokin
profil
immun
complet
vaccin
protocol
earli
late
time
point
experiment
challeng
l
chagasi
product
distinct
cytokin
evalu
vaccin
protocol
l
chagasi
sand
fli
saliva
experiment
challeng
analysi
level
consid
morbid
marker
ongo
cvl
quinnel
et
al
brachelent
et
al
chamizo
et
al
well
murin
model
vl
miral
et
al
observ
group
vaccin
lbsap
show
increas
level
compar
c
group
howev
increas
level
lbsap
group
also
observ
accord
manna
et
al
possibl
maintain
standard
resist
cvl
even
presenc
long
elev
level
nevertheless
result
suggest
typic
profil
link
cytokin
resist
suscept
pattern
cvl
similar
studi
previou
studi
manna
et
al
associ
resist
suscept
natur
l
chagasi
infect
cvl
contrast
level
splenocyt
dog
natur
infect
l
chagasi
present
differ
clinic
sign
indic
cytokin
could
biomark
present
cours
infect
cvl
lage
et
al
similarli
also
associ
suscept
cvl
pinelli
et
al
lage
et
al
alv
et
al
boggiatto
et
al
human
vl
nylen
sack
data
show
increas
level
lb
group
sap
group
contrast
observ
decreas
level
lbsap
relat
lb
group
vsastimul
pbmc
hypothes
lower
level
immun
protocol
lack
signific
level
experiment
challeng
l
chagasi
lbsap
contribut
establish
effici
immun
respons
vaccin
dog
addit
cytokin
associ
progress
leishmania
infect
murin
model
barral
et
al
virmondesrodrigu
et
al
gantt
et
al
studi
perform
cvl
howev
exist
studi
show
increas
level
asymptomat
symptomat
dog
natur
infect
l
chagasi
result
display
decreas
level
slcastimul
cultur
lbsap
group
result
suggest
vaccin
lbsap
may
trigger
reduc
product
experiment
challeng
fact
previou
work
alv
et
al
report
high
level
associ
increas
parasit
load
lymph
node
symptomat
dog
natur
infect
l
chagasi
associ
cytokin
cvl
morbid
therefor
possibl
reduc
level
associ
higher
level
l
chagasi
sand
fli
saliva
challeng
would
contribut
establish
immunoprotect
mechan
induc
lbsap
vaccin
type
cytokin
also
consid
prerequisit
evalu
immunogen
l
chagasi
experiment
challeng
anticvl
vaccin
clinic
trial
rei
et
al
thu
analyz
level
studi
establish
togeth
associ
resist
profil
cvl
pinelli
et
al
pinelli
et
al
chamizo
et
al
carrillo
et
al
alv
et
al
howev
consensu
profil
would
good
indic
resist
suscept
l
chagasi
infect
consid
similar
level
show
dog
present
distinct
clinic
sign
lage
et
al
moreov
lbsap
group
present
differ
level
compar
experiment
group
fact
data
similar
leishmun
result
present
differ
express
molecul
et
al
de
lima
et
al
addit
assess
level
group
immun
lbsap
reveal
increas
level
cytokin
presenc
vsa
stimul
compar
interestingli
higher
level
vaccin
protocol
relat
c
lb
group
vsastimul
cultur
earli
period
post
challeng
relat
sap
lb
group
slcastimul
cultur
hallmark
lbsap
group
sinc
cytokin
associ
protect
cvl
straussayali
et
al
menezessouza
et
al
high
level
impair
product
would
indic
establish
immunoprotect
mechan
induc
lbsap
vaccin
consid
import
proinflammatori
cytokin
establish
protect
immun
leishmania
parasit
induc
synthesi
activ
microbicid
function
macrophag
trinchieri
et
al
reiner
locksley
thu
consid
one
import
molecul
respons
kill
intracellular
parasit
leishmania
genu
heinzel
et
al
bogdan
sisto
et
al
gradoni
ascenzi
context
found
lbsap
group
increas
level
vaccin
protocol
present
sustain
improv
earli
late
time
point
l
chagasi
experiment
challeng
presenc
slca
stimulu
compar
interestingli
vaccin
protocol
lbsap
group
show
increas
level
vsa
slcastimul
cultur
compar
group
moreov
earli
late
period
post
challeng
lbsap
group
remain
produc
increas
level
leishmaniaspecif
compar
respect
stimul
cultur
vsa
slca
group
furthermor
increas
level
concomit
higher
amount
cultur
stimul
slca
vsa
sinc
associ
resist
profil
leishmania
infect
differ
experiment
model
squir
et
al
andrad
et
al
murray
et
al
carrillo
et
al
fernand
et
al
data
reveal
intens
leishmaniaspecif
induct
immun
lbsap
consid
lack
suffici
amount
biolog
materi
perform
pcr
analysi
assess
parasit
burden
howev
lbsap
lb
group
show
one
dog
posit
parasitolog
result
may
indic
antigen
l
braziliensi
induc
protect
experiment
l
chagasi
challeng
investig
focu
efficaci
lbsap
vaccin
protect
experiment
challeng
l
chagasi
use
quantit
pcr
conclus
data
point
promin
type
immun
respons
elicit
higher
level
follow
complet
vaccin
l
chagasi
challeng
addit
level
reduc
earli
immun
respons
l
chagasi
challeng
product
enhanc
late
time
point
follow
l
chagasi
challeng
furthermor
base
bone
marrow
parasitolog
analysi
frequenc
parasit
decreas
presenc
vaccin
antigen
thu
lbsap
vaccin
appear
elicit
promin
longlast
type
immunogen
